Drug Type T-lymphocyte cell therapy |
Synonyms Syngenon, BSG 001, BSG-001 |
Target |
Mechanism TLR modulators(Toll-like receptor modulators), Immunomodulators |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization BioSyngen Pte Ltd.Startup |
Active Organization- |
Inactive Organization BioSyngen Pte Ltd.Startup |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Malignant ascites | Phase 2 | AU | BioSyngen Pte Ltd.Startup | 01 Jan 2019 |
Malignant Pleural Effusion | Phase 2 | AU | BioSyngen Pte Ltd.Startup | 01 Jan 2019 |